Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia.
Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia.
Kidney Blood Press Res. 2019;44(4):792-809. doi: 10.1159/000501688. Epub 2019 Aug 20.
We evaluated the hypothesis that the development of renal dysfunction and congestive heart failure (CHF) caused by volume overload in rats with angiotensin II (ANG II)-dependent hypertension is associated with altered renal vascular responsiveness to ANG II and to epoxyeicosatrienoic acids (EETs).
Ren-2 transgenic rats (TGRs) were used as a model of ANG II-dependent hypertension. CHF was induced by volume overload achieved by the creation of the aorto-caval fistula (ACF). Renal blood flow (RBF) responses were determined to renal arterial administration of ANG II, native 11,12-EET, an analog of 14,15-EETs (EET-A), norepinephrine (NE), acetylcholine (Ach) and bradykinin (Bk) in healthy (i.e., sham-operated) TGR and ACF TGR (5 weeks after ACF creation).
Selective intrarenal administration of neither vasoactive drug altered mean arterial pressure in any group. Administration of ANG II caused greater decreases in RBF in ACF TGR than in sham-operated TGR, whereas after administration of NE the respective decreases were comparable in the 2 groups. Administration of Ach and Bk elicited significantly higher RBF increases in ACF TGR as compared with sham-operated TGR. In contrast, administration of 11,12-EET and EET-A caused significantly smaller RBF increases in ACF TGR than in sham-operated TGR.
The findings show that 5 weeks after creation of ACF, the TGR exhibit exaggerated renal vasoconstrictor responses to ANG II and reduced renal vasodilatory responses to EETs, suggesting that both these alterations might play an important role in the development of renal dysfunction in this model of CHF.
我们评估了这样一个假设,即在血管紧张素 II(ANG II)依赖性高血压大鼠中,由容量超负荷引起的肾功能障碍和充血性心力衰竭(CHF)的发展与肾脏血管对 ANG II 和环氧二十碳三烯酸(EETs)的反应性改变有关。
使用 Ren-2 转基因大鼠(TGR)作为 ANG II 依赖性高血压的模型。通过创建腔静脉-腹主动脉瘘(ACF)来实现容量超负荷,从而诱导 CHF。在健康(即假手术)TGR 和 ACF TGR 中,通过向肾动脉给予 ANG II、内源性 11,12-EET、14,15-EETs 类似物(EET-A)、去甲肾上腺素(NE)、乙酰胆碱(Ach)和缓激肽(Bk)来确定肾血流(RBF)反应。
在任何一组中,选择性的肾内给予血管活性药物均未改变平均动脉压。在 ACF TGR 中,ANG II 的给药引起的 RBF 降低幅度大于 sham-operated TGR,而在 2 组中,NE 的给药引起的相应降低幅度相当。与 sham-operated TGR 相比,ACF TGR 中 Ach 和 Bk 的给药引起的 RBF 增加幅度显著更高。相比之下,在 ACF TGR 中,11,12-EET 和 EET-A 的给药引起的 RBF 增加幅度明显小于 sham-operated TGR。
这些发现表明,在创建 ACF 5 周后,TGR 表现出对 ANG II 的肾血管收缩反应增强,对 EET 的肾血管舒张反应减弱,这表明这两种改变可能在这种 CHF 模型中肾功能障碍的发展中发挥重要作用。